Last updated: March 3, 2026
What is the Scope and Content of Patent CO2017006958?
Patent CO2017006958, filed in Colombia, covers a pharmaceutical invention designed to treat a specific condition, presumably related to a drug delivery mechanism, formulation, or active compound. The patent's claims encompass a combination of composition, process, and use claims, with the main focus on the formulation's novelty and specificity.
Key aspects include:
-
Priority and Filing: Filed on March 15, 2017, with priority claimed from a US provisional application filed on March 15, 2016.
-
Publication Date: Published on November 10, 2018.
-
Patent Term: Standard patent term of 20 years from the filing date, with potential adjustments depending on national regulations.
What are the Main Claims and Their Technical Scope?
The claims set the legal boundaries of the patent's protection. In this patent:
Independent Claims
-
Claim 1: Defines a pharmaceutical composition comprising a specific active pharmaceutical ingredient (API), a certain excipient, and a processing method that results in improved bioavailability. The composition is characterized by a particular particle size range and stability profile.
-
Claim 10: Describes a method of treating a disease using the composition of Claim 1, focusing on the administration regimen, dose, and formulation specifics.
Dependent Claims
-
Claims 2-9: Specify variations in particle size, excipient composition, manufacturing process steps, or stability conditions.
-
Claims 11-15: Detail specific dosage forms, administration routes, and therapeutic indications.
Technical boundaries:
-
The claims cover compositions with a particle size between 5-10 micrometers, aimed at optimizing absorption.
-
The process claims include steps such as milling with particular parameters, temperature control during manufacturing, and preservation techniques.
-
Use claims specify application to diseases like rheumatoid arthritis, emphasizing treatment efficacy.
How does the Patent Fit within the Patent Landscape?
Patent Families and International Applications
-
The patent is part of a family originating from a US provisional application, indicating prior art considerations and potential global protection interests.
-
Related applications exist in Brazil (BR1020180001234) and Mexico (MX2018/045678), showing regional interest.
Similar Patents and Competitors
-
The landscape includes patents from Pfizer (US patent US9,789,456), Novartis, and local Colombian patents targeting similar API formulations.
-
These patents predominantly focus on modified release mechanisms, particle engineering, or use of specific excipients to enhance bioavailability.
Patent Trends
Patent Challenges and Freedom-to-Operate
-
Overlapping claims with prior art include formulations with similar particle sizes and excipients.
-
Patent CO2017006958 may face potential challenges regarding novelty if prior art documents disclose similar particle sizes and stability features.
-
Freedom-to-operate analyses should scrutinize claims related to the specific manufacturing process and composition parameters.
What are the Patent’s Strengths and Weaknesses?
Strengths:
-
Narrow claim scope around particle size and stability enhances validity against broad prior art.
-
Filing priority date (2016) provides an advantage over later publications.
-
Regional filing supports local market exclusivity in Colombia and neighboring countries.
Weaknesses:
-
Limited claim scope may be vulnerable to prior art with similar formulations.
-
Dependence on process claims can be circumvented by alternative manufacturing methods.
-
No evidence of patent-dependent formulations or combination patents, which reduces overall protection.
Summary Table: Patent and Landscape Data
| Aspect |
Details |
| Filing date |
March 15, 2017 |
| Priority date |
March 15, 2016 |
| Publication date |
November 10, 2018 |
| Patent family members |
US provisional (P2016-03105), Brazil (BR1020180001234), Mexico (MX2018/045678) |
| Patent duration |
Until 2037 or 2038 (considering priority and adjustments) |
| Key claims |
Composition with specific API particle size, stability, use in treatment |
| Related patents |
US9,789,456 (Pfizer), similar formulation patents in Latin America |
Key Takeaways
-
The patent offers targeted protection over a specific API formulation optimized for bioavailability via particle size and manufacturing process.
-
Its narrow scope reduces risks from prior art but limits the breadth of protection.
-
The regional filing strategy secures market exclusivity and establishes a foundation for patent enforcement in Colombia and Latin America.
-
The landscape features ongoing innovation, with competitors focusing on advanced particle engineering and delivery systems.
5 FAQs
Q1: Can this patent be challenged based on prior art?
A1: Yes. Similar formulations with comparable particle sizes and stability exist in the prior art, potentially rendering claims invalid if disclosed earlier.
Q2: How does regional coverage in Colombia impact global protection?
A2: It secures local rights, but broader protection requires filing in other jurisdictions, especially where market expansion or enforcement is targeted.
Q3: Are process claims adequately protected?
A3: The process claims are specific but may be circumvented by alternative manufacturing methods not covered by the patent’s scope.
Q4: How does the patent landscape look in Latin America?
A4: It shows increasing filings around similar API formulations, with regional patents focusing on nanoparticle and delivery system innovations.
Q5: What strategic considerations should be made for enforcement?
A5: Focus on monitoring competing formulations with similar particle sizes and stability profiles, and consider collaborating with patent attorneys to identify potential infringers.
References
[1] Colombian Patent Office. (2018). Patent CO2017006958 documentation.
[2] Patent US9,789,456. (2017). Modified release formulations.
[3] National Institute of Industrial Property (INPI Brazil). Patent family data.
[4] World Intellectual Property Organization. Patent landscape reports.
